Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751372 | 0.81 | AAK1 (0.38) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL1581324 | 0.81 | ATR (0.42) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL29364468 | 0.81 | ATR (0.42) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL1427984 | 0.81 | AAK1 (0.38) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL12097975 | 0.81 | BRD9 (0.39) | METAP1AAK1ATRBRD9MAPKAPK2 | |
| SCHEMBL594117 | 0.80 | CYP17A1 (0.40) | METAP1AAK1ATRBRD9GSK3B | |
| SCHEMBL1430094 | 0.78 | ATR (0.38) | METAP1AAK1ATRBRD9GSK3B | |
| SCHEMBL13568083 | 0.77 | METAP1 (0.36) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL1492572 | 0.77 | METAP1 (0.36) | METAP1TRPA1AAK1ATRBRD9 | |
| SCHEMBL5778030 | 0.77 | RXFP1 (0.40) | ARMETAP1ATRBRD9GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | EGLN2 4467/4885GPR119 57/4885AR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.